PDF herunterladen
Der Nuklearmediziner 2018; 41(03): 247-252
DOI: 10.1055/a-0621-3216
PET Update 2018
© Georg Thieme Verlag KG Stuttgart · New York

Somatostatinrezeptor-PET

Somatostatin receptor PET
Alexander Haug
Klinisches Institut für Nuklearmedizin, AKH Wien/Medizinische Universität Wien, Wien, Österreich
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
07. September 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Die SSTR-PET/CT ist Goldstandard in der Bildgebung von G1-/G2-NET. Sie hat eine signifikant höhere diagnostische Genauigkeit als die CT, erlaubt eine zuverlässige Primär- und Rezidivdiagnostik, und hat dadurch einen signifikanten Einfluss auf das therapeutische Management von Patienten mit NET. Eine Therapie mit kalten SSA muss für die SSTR-PET nicht unterbrochen werden. Die SSTR-PET/MRT kann sicherlich noch nicht als Standard angesehen werden, kann aber insbesondere bei Leber- und Knochenmetastasen hilfreich sein. Neue Entwicklungen in Richtung antagonistische SSA sind vielversprechend.

Abstract

SSTR-PET/CT is currently considered as gold standard in imaging of G1/G2-NET. The diagnostic accuracy of SSTR-PET/CT is significantly higher than CT, enables reliable imaging of primary and recurrent NET and has a significant impact on therapeutic management of patients suffering from NET. Treatment with cold SSA does not have to be interrupted before SSTR PET. Surely, SSTR PET/MRI cannot yet be considered a standard, but can be particularly helpful in liver and bone metastases. New developments towards antagonistic SSA are promising.

Schlüsselwörter

Neuroendokriner Tumor - PET - Somatostatinrezeptor - 68Gallium

Keywords

Neuroendocrine tumour - PET - Somatostatin receptor - Gallium-68
 

  • Literatur

  • 1 Yao JC, Hassan M, Phan A. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26 (18) 3063-3072
    CrossrefPubMedGoogle Scholar
  • 2 Schillaci O. Somatostatin receptor imaging in patients with neuroendocrine tumors: not only SPECT?. J Nucl Med 2007; 48: 498-500
    CrossrefPubMedGoogle Scholar
  • 3 Kabasakal L, Demirci E, Ocak M. et al. Comparison of (68)Ga-DOTATATE and (68)Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012; 39: 1271-1277
    CrossrefPubMedGoogle Scholar
  • 4 Poeppel TD, Binse I, Petersenn S. et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011; 52: 1864-1870
    CrossrefPubMedGoogle Scholar
  • 5 Gabriel M, Decristoforo C, Kendler D. et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518
    CrossrefPubMedGoogle Scholar
  • 6 Srirajaskanthan R, Kayani I, Quigley AM. et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010; 51: 875-882
    CrossrefPubMedGoogle Scholar
  • 7 Sadowski SM, Neychev V, Millo C. et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34: 588-596
    PubMedGoogle Scholar
  • 8 Bozkurt MF, Virgolini I, Balogova S. et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging 2017; 44: 1588-1601
    CrossrefPubMedGoogle Scholar
  • 9 Boy C, Poeppel T, Kotzerke J. et al. [Somatostatin receptor PET/CT (SSTR-PET/CT)]. Nuklearmedizin 2018; 57: 4-17
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 10 Haug AR, Rominger A, Mustafa M. et al. Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors. J Nucl Med 2011; 51: 1679-1683
    PubMedGoogle Scholar
  • 11 Haug AR, Cindea-Drimus R, Auernhammer CJ. et al. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med 2012; 53: 1686-1692
    CrossrefPubMedGoogle Scholar
  • 12 Prasad V, Ambrosini V, Hommann M. et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2010; 37: 67-77
    CrossrefPubMedGoogle Scholar
  • 13 Barrio M, Czernin J, Fanti S. et al. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. J Nucl Med 2017; 58: 756-761
    CrossrefPubMedGoogle Scholar
  • 14 Ilhan H, Fendler WP, Cyran CC. et al. Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ann Surg Oncol 2015; 22: 164-171
    CrossrefPubMedGoogle Scholar
  • 15 Koch W, Auernhammer CJ, Geisler J. et al. Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography. Mol Imaging 2014; 13: 1-10
    PubMedGoogle Scholar
  • 16 Haug AR, Auernhammer CJ, Wangler B. et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010; 51: 1349-1356
    CrossrefPubMedGoogle Scholar
  • 17 Ruf J, Schiefer J, Furth C. et al. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 2011; 52: 697-704
    CrossrefPubMedGoogle Scholar
  • 18 Kwekkeboom DJ, de Herder WW, Kam BL. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130
    CrossrefPubMedGoogle Scholar
  • 19 Gabriel M, Oberauer A, Dobrozemsky G. et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009; 50: 1427-1434
    CrossrefPubMedGoogle Scholar
  • 20 Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959
    CrossrefPubMedGoogle Scholar
  • 21 Boninsegna L, Panzuto F, Partelli S. et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 2012; 48: 1608-1615
    CrossrefPubMedGoogle Scholar
  • 22 Welin S, Stridsberg M, Cunningham J. et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009; 89: 302-307
    CrossrefPubMedGoogle Scholar
  • 23 Haug AR, Cindea-Drimus R, Auernhammer CJ. et al. Neuroendocrine Tumor Recurrence: Diagnosis with 68Ga-DOTATATE PET/CT. Radiology 2012; 53: 1686-1692
    PubMedGoogle Scholar
  • 24 Berzaczy D, Giraudo C, Haug AR. et al. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Clin Nucl Med 2017; 42: 669-674
    CrossrefPubMedGoogle Scholar
  • 25 Sawicki LM, Deuschl C, Beiderwellen K. et al. Evaluation of (68)Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with (68)Ga-DOTATOC PET/CT. Eur Radiol 2017; 27: 4091-4099
    CrossrefPubMedGoogle Scholar
  • 26 Ginj M, Zhang H, Waser B. et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006; 103: 16436-16441
    CrossrefPubMedGoogle Scholar
  • 27 Nicolas GP, Schreiter N, Kaul F. et al. Comparison of (68)Ga-OPS202 ((68)Ga-NODAGA-JR11) and (68)Ga-DOTATOC ((68)Ga-Edotreotide) PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Evaluation of Sensitivity in a Prospective Phase II Imaging Study. J Nucl Med 2018; 59: 915-921
    CrossrefPubMedGoogle Scholar